Skip to main content

Governing industry involvement in the non-communicable disease response in Kenya

Abstract

Background

In low- and middle-income countries (LMICs), multinational companies have become increasingly involved in addressing public health challenges. Dealing with companies as partners in health sector development creates new challenges for governments. We sought to develop an approach to assess the existence and effectiveness of governance structures that can ensure that industry-led public health initiatives contribute to development.

Methods

We developed a governance assessment tool based on the principles of the Paris Declaration for Aid Effectiveness and other related agreements. We applied it to the case of pharmaceutical companies’ involvement in the Kenyan response to non-communicable diseases (NCDs). We gathered data for analysis through 46 stakeholder interviews and reviewing documents.

Results

The Kenyan government has informal norms in place regarding program governance and strategy, but it has yet to issue formal regulations. While enabling elements exist that support initiatives to develop in alignment with these norms, implementation is often hindered by a lack of resources. Currently, broad stakeholder support for filling these gaps has created a window of opportunity for action.

Conclusion

The application of the proposed assessment tool illustrates its viability for assisting companies and governments alike in defining governance needs for industry-led public health initiatives. Our findings in Kenya provide example considerations for LMICs working to integrate industry-led public health programs into the health system. Bilateral and multilateral donors also have important roles in strengthening LMICs’ capacities to govern multinational corporations’ contributions to NCDs in particular, and development in general.

Background

Transnational corporations, including those in the pharmaceutical industry, have gradually been taking on more proactive roles in national-level development, acting as development partners with governments and non-governmental organizations (NGOs) in many low- and middle-income countries (LMICs) [1,2,3]. Especially the passing of the UN Agenda 2030 has again emphasized the ambition of countries and international organizations to work with and through the private sector to achieve the Sustainable Development Goals [4,5,6]. Both practitioners and scholars suggest that companies can bring different capacities and additional resources to the table to solve problems that require multi-sectoral approaches [2, 7, 8].

In global health, the number of access-to-medicines and other global health initiatives involving pharmaceutical companies or their foundations has significantly increased in recent years [9]. Pharmaceutical companies have taken on especially strong roles as development partners for LMICs addressing non-communicable diseases (NCDs) [10]. The industry has both expertise and strategic interests in supporting LMIC’s NCD response, as medicines for NCDs constitute the core business of many pharmaceutical companies [11]. Most other global health donors are still shying away from NCDs and continue to focus on other health challenges [12].

Research on the role of business in development has repeatedly pointed out that there is – at best - only anecdotal evidence to support the assumed positive effect of multinational companies acting as development agents [13,14,15,16]. Thus, global health scholars and policymakers are divided over the desirability of the growing involvement of pharmaceutical and other companies in public health efforts in LMICs. Some perceive it as an opportunity to tap into additional resources and expertise [17, 18]. Those with more critical perspectives are concerned that companies use their involvement to gain more influence in global health governance [19, 20]. Critics have also identified risks of industry involvement in countries’ health systems [21, 22]: because corporate interests do not necessarily align with public health priorities, corporate development initiatives may lead to undesirable diversion of limited local resources. Corporations might also gain undue influence through these activities that they could later use to steer future decision-making to their own advantage. To address these concerns, advocates have suggested that it is important for LMICs’ governments to actively steer and regulate private sector involvement [17, 21, 22]. The World Health Organization (WHO) has developed a checklist for governments dealing with corporate access to medicines initiatives [21]—however, gaps remain in understanding the extent to which this or other proposed structures and processes for stronger governance have been adopted by countries.

Thus, this paper asks: how and to what extent can LMIC governments govern industry involvement in development initiatives? What challenges do governments face, and what lessons can we derive from their current efforts? The paper begins by reviewing the principles for governance of health and development initiatives that we integrated into an assessment tool. We then use the tool to focus on the case of Kenya, which has been a leader among LMICs in experimenting with industry involvement in responding to the expanding challenge of NCDs.

Thereby the paper aims to assess the degree to which the Kenyan government has already implemented governance structures and processes to promote the effectiveness of pharmaceutical corporations’ involvement in the NCD response. It highlights some of the challenges this effort has faced and derives lessons from Kenya’s experience for other countries dealing with a growing number of industry-led programs.

The Paris declaration on aid effectiveness as a governance framework

In 2005, more than 100 donor and aid-receiving countries, as well as major international NGOs and multilateral institutions, agreed on the Paris Declaration on Aid Effectiveness [23], which lays out a set of five partnership principles for development: country ownership of development efforts, alignment with local systems and priorities, harmonization among initiatives, managing for results, and mutual accountability. The 2008 Accra Agenda for Action [23] affirmed these principles and added stakeholder inclusivity as a sixth element. While the effectiveness of donor aid also depends on other factors, many of which are case- or country-specific, these principles represent a set of necessary or enabling conditions and rights-based norms.

The Paris Declaration is the leading framework on how to conduct development cooperation. The Paris Declaration does not explicitly address the private sector, but there is no reason to assume that its principles would be less valid for corporations when they act as development partners [24]. International global health donors further committed to a sector-specific application of these principles in the 2007 International Health Partnership [25]. In 2016, IHP evolved into the UHC2030 coalition, whose “Global Compact” also directly refers to the Paris Declaration [26].

There is an established practice of referring to these principles in academic work that analyzes and evaluates corporate global health efforts [20, 22, 27,28,29]. Recent actions to lay out guidelines for the pharmaceutical industry’s global health efforts, such as the WHO policy brief or the partnership principles of the industry’s Access Accelerated alliance, also build on the Paris Declaration [21, 30]. Table 1 shows how the guiding principles are presented in these different documents, from the general aid effectiveness agenda to the specific case of NCDs. The column on the far-right offers several examples of why following aid principles is not necessarily in companies’ interests. These include concerns about the costs involved in collaboration processes, losing control of corporate resources, and being forced to act against their own profit-making interests. Given potential inconveniences and conflicts of interest, governments cannot rely on companies’ adherence to established, but voluntary, principles in international aid.

Table 1 Aid effectiveness principles and potential challenges

Pharmaceutical industry-led NCD initiatives in Kenya

With 27 individual corporate programs by 11 different pharmaceutical companies running in January 2020, Kenya was the country with the greatest number of industry-led NCD programs, according to the monitoring platform Access Observatory (www.accessobservatory.org). Industry-led programs have explicit social goals and are often structured as cross-sector partnerships between companies, NGOs, and government agencies [3]. Yet, they differ from more traditional global health partnerships [31] in that they are “designed and co-financed by companies and companies take responsibility and credit for them” [28]. Whilst most companies work through their Kenyan business or their in-house corporate responsibility department, two of the eleven companies primarily work through their corporate foundations. Even though foundations are technically independent, in this paper, we treat them as extensions of their mother companies, as companies take credit for their work and corporate executives usually lead the foundations’ governance. In Kenya, industry-led programs were mainly focused on cancer care, diabetes, and cardiovascular diseases. While some programs were primarily providing access to health products, the majority also involved elements of strengthening or providing health services, such as supporting health worker training, sponsoring screening campaigns and even development of policy and guidelines [32].

The international pharmaceutical industry has always had a large footprint in Kenya. Many companies have established their regional offices in the country, which constitutes one of Africa’s most promising growth markets, works as a regional logistics hub, and has a market-friendly political system. The launch of Access Accelerated (AA) in January 2017 reinforced industry involvement in Kenya’s NCD response. AA is an industry-led alliance of more than twenty pharmaceutical companies collaborating with the World Bank, PATH, NCD Alliance, City Cancer Challenge, World Heart Federation, and RTI International to improve NCD care. AA engages in its own projects as well as serving as a coordination and standard-setting mechanism for industry-led NCD initiatives. In 2018, AA selected Kenya to be one of two pilot countries for deeper industry involvement in the NCD response.

Similar to global trends, NCDs have recently increased in political relevance in Kenya. The first NCD policy to be developed in Kenya was the National Diabetes Strategy in 2010, supported by the World Diabetes Foundation (WDF), which is funded by the company Novo Nordisk [33]. With increasing NCD prevalence and disease burden, more civil society organizations began pushing for NCDs, especially cancer, to be taken seriously [34]. As a result of this attention and ongoing advocacy, various national NCD policies and legislative documents have been developed [35,36,37,38]. However, implementation of the policies has been inconsistent. It differs by county, as Kenya’s devolved constitution grants fiscal, political and operational responsibility for health services to county-level governments [39]. Further, there is a persistent lack of available resources for NCD services. Only a few development partners have thus far engaged in the NCD response, and domestic funding for health remains too limited to cover the necessary budgets. In the face of the growing public health need, and in light of the lack of available resources, national- and county-level actors turned to pharmaceutical companies as possible development partners in the Kenyan NCD response.

In line with the devolution process and the “Kenya Health Policy 2014-2030” [40], the Kenyan government has been working on improving governance structures and processes to manage health sector partnerships. Most notably, the Ministry of Health, with support from WHO, is currently developing a new “Kenya Health Sector Partnership and Coordination Framework” [41], which aims to guide management of all types of partnerships, including with NGOs and the private sector, as well as with bilateral and international donors. This remains an ongoing process, and thus far has not primarily focused on industry-led programs.

Methods

Data collection

To assess how Kenya has implemented governance structure and processes for industry-led NCD programs, this paper builds on data that were collected from primary and secondary sources in two phases. Between June and December 2019, we collected gray literature (including government documents, reports by international organizations or donors, academic articles) on the Kenyan response to NCDs; we also gathered reports from AA and the pharmaceutical companies about industry activities in the country. We captured existing stakeholder statements about industry-led NCD initiatives that we found in online news media and in videos of public events such as NCD stakeholder forums and panel discussions available on YouTube. We also extracted the Access Observatory’s data for Kenya to get an overview of which companies were working on which issues, and with which partners and strategies.

Based on the findings from that phase of data collection, we mapped stakeholders to identify organizations involved in the NCD space. Following a snowball sampling strategy, we started interviewing existing contacts within these organizations and asked them for links to other stakeholders. In total, we conducted 46 semi-structured interviews with stakeholders from five sectors: the public sector (national and county government agencies and ministries); the private sector (transnational and local pharmaceutical companies, industry associations); civil society (patient and disease advocacy organizations, NGOs); international organizations (donor agencies, UN agencies); and the health sector (medical professional associations, health service delivery institutions). All interviewees were either directly managing projects involving pharmaceutical companies or held senior management positions in their respective organizations. The interviewees’ organizations are listed in Table 2. The interviews, which were recorded, lasted between 26 and 103 min. Subsequently, we transcribed all interviews. We obtained the interviewees’ consent to record their interviews and assured them that they would remain anonymous. Thus, quotes are not attributed to names, job titles, or organizations, but only refer to the interviewee’s sector (government, health services, civil society, pharmaceutical industry). The project underwent ethics review by Strathmore University’s Institutional Review Board (SU-IERC0574/19).

Table 2 Overview of interviewees by sector

Data analysis

While different tools exist to assess the internal governance of individual programs and partnerships [27, 42], we did not find any framework to study the overarching governance of involving industry-led NCD programs in the health system. Thus, we developed an assessment tool based on the principles of the Paris Declaration. Our goal was to identify a set of governance elements that governments could put in place to shape how companies adhere to these principles. In this framework we grouped the principles of alignment and harmonization together, as both affect the design of program strategies. Management by results and accountability were analyzed together as benchmarks for governing program implementation. Finally, ownership and stakeholder inclusion were included as cross-cutting procedural principles, highlighting the roles that governments and affected groups should play in deciding about strategy as well as being involved in program implementation.

We identified both regulatory and enabling elements [43]. Regulatory elements are rules and norms about how corporations design and govern programs. These could be either formalized in policies or guidelines or just exist as informal norms. Regulatory elements have sanction mechanisms for non-compliance—these may be formal or informal, such as refusing to grant permission for program activities, withdrawing public resources, or damaging a company’s reputation. Enabling elements are any activities or structures that make it easier for corporations to adhere to the principles, such as provision of public data for needs assessments, or conducting stakeholder forums that corporations could use for better harmonization. In sum, country governance frameworks can shape the adherence of companies to the guiding principles in two ways: turning guiding principles into enforceable local rules and norms, and by assisting companies to set their programs up according to the principles.

Our selection of governance elements for assessment draws on three sources: First, on thoughts about governance frameworks for cross-sector partnerships [43, 44]. Second, we adopted suggestions made by the WHO for country responses to incorporate access to medicine initiatives which we described in the introduction and Table 1. Third, we identified relevant governance elements from the draft “Kenyan Health Sector Partnership and Coordination Framework” [41], which remained under review at the time of writing. We assigned each element to a single principle of the Paris Declaration for parsimony’s sake, even though some may be associated to multiple principles. Review meetings, for example, are certainly both important for managing by results and accountability alike.

Table 3 presents an overview of the assessment tool. The left column lists the Paris Declaration Partnership principles. The next column includes the regulatory and enabling elements as described above. The column furthest on the right lays out how each governance element can shape adherence to a given principle and as well as questions to assess a specific case. We used the assessment questions to code our interview transcripts with the help of the software MAXQDA and to review archival data in order to obtain answers to each individual question of our framework. If interviewees had conflicting perspectives on a question, we corroborated accounts through additional interviews or document review and report these nuances in the results section.

Table 3 Assessment tool

Results

Partnership principles in program strategy

Kenya’s National NCD Strategy 2015–2020 [35] underlines a need for cross-sector partnerships, but it does not specify expectations about how partnerships develop their strategies. Although there are no formal policies or laws guiding the design of industry-led NCD programs, informal local norms exist that govern how companies should act if they intend to launch a NCD program (see Table 4 below for a summary). In our interviews, representatives of the national government clearly stated their demands for strong government ownership, including expecting to be consulted on any corporate activities that are linked to the health system. One industry representative recognized this:

“We strongly engaged with the NCD department in the Ministry of Health. Together we came up with a good approach. They were of the mindset of wanting to work with pharma in improving NCD care. Their only request was to not create parallel health systems and align well. If we kept them informed about anything we did, they would be happy to work alongside us.” (Interview #31, industry representative)

As the quote alludes to, technical experts in the public sector explicitly demanded that companies developed programs that aligned with local priorities and systems. Since companies often rely on the public health infrastructure for the implementation of their programs or need to cooperate with regulatory bodies, the government has leverage opportunities to pressure the companies to meet its expectations.

Table 4 Kenya Results: Program strategy

However, the degree of government representatives’ insistence on its norms can vary on a case-by-case basis. According to other accounts, norms have at times been undermined. A civil society representative, for instance, asserted that high-level political leaders sometimes agree to companies’ preferences before technical experts were consulted.

“Companies will not come and negotiate with the Ministry’s NCD division. They go to a higher office. Then, the project is brought to you as an order from above. So, in as much as on the technical level you are able to give these inputs and set conditions for when you are coming to do a NCD project, this is the biggest challenge.” (Interview #29, civil society representative)

Misalignments between corporate and public health interests have produced huge inefficiencies in programming. For example, in one case a company prohibited an NGO from using funds provided to screen for diabetes to also screen for cardiovascular conditions, as the company was only interested in diabetes. However, government and civil society were often hesitant to push companies on adhering to partnership principles, as they fear the loss of corporate support.

“So when they said, ‘no these are our priorities at the moment, ‘we had to make a decision and say, ‘Okay, it's better to focus on something than nothing.’ I think we just agreed to give in … It's just that we felt that maybe if we asked for too much they might decide to go elsewhere.” (Interview #44, civil society representative)

For companies that are willing to ensure the alignment of their programs with national priorities, a broad set of national policies and disease-specific strategies exist and are easily accessible. However, on the county level priorities are less clear. While county development plans broadly address the health sector, few counties have laid out specific plans related to NCDs. Moreover, interviewees reported that it is difficult to get access to reliable data on disease prevalence and health systems capacities, making it difficult to understand the needs. Publicly provided data are incomplete in many cases; in other counties, the data simply do not exist:

„The information system is also what we lack … we don't have a sufficient data registry on cancer that's national. So decisions are being made on emotional grounds.” (Interview #21, civil society representative).

Still data availability is gradually improving, but some interviewees expressed concern that growing pressure to protect patient data more strictly might make it more difficult for non-state actors to access data in the future.

We need to point out that some companies voluntarily pushed for strong alignment of their programs with local priorities. One company for instance, invested time and resources into a bottom-up approach of developing a program improving cancer care. It invited stakeholders from different sectors for several meetings to discuss about priorities, intervention strategies and possible partners who now also lead and oversee the program’s implementation. In some cases, such companies were also able to build on ad-hoc support from the government to achieve alignment. Interviewees reported that the national Ministry of Health assigned technical staff to help develop program strategies, for example by advising on the selection of counties in which to operate:

„We engaged with the Ministry of Health at high level who then cascaded it down and appointed a team to work with us.” (Interview #16, industry representative).

The NCD division of the Ministry of Health has grown substantially; however, it still has limited human and financial resources when compared with other divisions in the Ministry. Thus, it could not assist the growing number of potential industry partners approaching it for support on an ad-hoc basis. In order to deal with limited resources, and to empower local stakeholders, the NCD division works closely with civil society organizations on governance of the sector. To this end, the NCD Strategy of 2015 proposed the creation of an NCD Interagency Coordinating Committee and various technical working groups (TWGs) on specific themes. Government representatives explained that companies are expected to submit their program ideas to the relevant TWG, thereby ensuring alignment and stakeholder involvement at the same time. However, the potential effectiveness of this structure has been undermined by budgetary constraints and frequent leadership changes in the Ministry of Health. While several TWGs have become operational, companies relied on their own networks for stakeholder engagement in previous years.

“We selected the key players that we worked with at the time. Yet I was not sure if we got all the right and necessary stakeholders back then. Since then we did a lot of rejigging.” (Interview #31, industry representative)

The Kenyan government has regularly called on companies to invest more in harmonization among their initiatives—this represents another informal norm. Many interviewees including government representatives complained publicly about inefficiencies that result from companies’ unwillingness to collaborate effectively.

Everyone wants exclusivity, but I say: “The other company came last week and had almost the same program as you. Since you are not competing would you be able to partner so we use the same platform?”(Public statement, government representative [45])

Despite its calls, the government provides only limited support for harmonization. For example, there is no public registry of ongoing programs addressing NCDs. This makes it harder for potential new partners to obtain an overview of which actors are already working, in which counties, and on what issues. Government representatives also mentioned that initiatives are sometimes launched without their knowledge, especially when partners either go to the county level or decide to fund NGO activitiesdirectly.

“I think that quite a number fall through the cracks and the Ministry also gets to know about them after private sector players have already engaged with the counties or facilities.” (Interview #24, government representative)

In 2018, the national government and the international NGO PATH undertook a stakeholder mapping exercise that was supposed to be the foundation of a standing oversight platform. Several interviewees noted that this effort missed many initiatives and has not been regularly updated. These gaps are partially remedied by the existence of the Access Observatory, a database of programs financed by Access Accelerated [46]. However, the information listed in the Observatory is neither detailed enough for harmonization at the county level, nor does it include non-corporate NCD programs. Moreover, several interviewees suggested that the platform is not well-known among Kenyan stakeholders.

The government could improve harmonization by hosting regular joint planning forums with partners working on NCDs. We found a successful example of such a government-led multi-stakeholder NCD forum in the Kenyan cancer space – albeit without industry participation [34]. The TWGs of the NCD Interagency Coordinating Committee are providing such a platform in some disease areas, too. The Kenyan government has also hosted several broad NCD stakeholder meetings with the support of Access Accelerated; however, according to interviewees the conferences did not incorporate joint planning or coordination exercises and mainly had a representative function.

“Understanding the dynamic and bringing people together, to have a conversation and to agree on the direction and on the implementation model—Access Accelerated currently has not done this very well. Everyone comes to the platform and showcases what they're doing differently and nothing is coordinated to exploit each other’s strengths and competences.”(Interview #1, industry representative)

Beyond government, international organizations and major donors meet regularly at the Development Partners in Health roundtable for the purpose of harmonizing their programs. However, the roundtable has not yet put NCDs on its agenda. Further, it does not recognize corporations as development partners. Thus, companies cannot participate in its meetings. Moreover, we have found that - in some counties - existing multi-stakeholder consortia are assuming the role of ensuring harmonization and alignment of industry-led NCD initiatives. For example, the Academic Model for Providing Healthcare (AMPATH), a strategic partnership between Moi University, Moi Teaching and Referral Hospital and a group of North American and European Universities led by University of Indiana originally known for its HIV programs, has helped multiple pharmaceutical companies to develop and implement NCD initiatives in line with local needs, as well as harmonizing their corporate partners’ activities [30, 47]. Similarly, the “Blueprint for Innovative Healthcare Access” consortium of healthcare providers and NGOs tries to coordinate among multiple industry partners willing to launch NCD programs and points them to needs and gaps in the counties where it operates.

“We look for partners to come in and help with the gaps that we are experiencing.” (Interview #34, civil society representative)

Partnership principles in program implementation

As summarized in Table 5, we found no laws or rules regulate how corporate programs should govern the programs they implement. Interviewees said that the public sector does not strongly promote monitoring and evaluation frameworks, nor does it place a high priority on their development. Thus, there are also no informal norms that could nudge companies towards adherence to the principle of managing by results.

“The government did not give us clear requirements on reporting. There were some local standard things that local partners know and many were already collecting that information.” (Interview #31, industry representative)

Programs that deliver health services, including screening, diagnosing or treating patients, are bound by local regulations to report on basic indicators - such as the number of cases of a specific disease treated - to the general Kenyan health information system. Yet, company representatives explained that the existing public health information system mostly captures output indicators. It is not sufficiently elaborate to inform a unified results framework that could guide outcome-oriented management for more complex NCD programs. To fill this gap, companies can draw on a repository of logic models and indicators offered by the Access Observatory, but some have resorted to independently developing their own results management frameworks. Moreover, in some cases, prominent implementing partners, for example the previously mentioned AMPATH consortium in Western Kenya, may push companies to install ambitious monitoring and evaluation systems in their NCD initiatives [47, 48].

Table 5 Kenya Results: Program governance

We identified very few norms, either formal or informal, regarding accountability. Government representatives stated in interviews that they wanted companies to respect their leadership and to inform them about and invite them to any activities related to the public sector, such as capacity development for public sector health workers or the dissemination of health management guidelines.

“We do it in partnership with them. We would be very cross with them when they did the training without our involvement.” (Interview #24, government representative)

Beyond that, however, there seemed to be no expectations regarding reporting modalities, transparency, or involving government and stakeholders in decision-making and oversight bodies. If invited by companies, government representatives agreed to join oversight or advisory bodies of programs with formal governance structures. However, government representatives explained that they do not have the capacity to be closely involved in individually monitoring all industry-led programs.

“In terms of government monitoring, it is not an organized space. But it can only happen if there are functional technical working groups. Now there is the National Cancer Institute, but it is yet to be fully commissioned.” (Interview #21, civil society representative)

Neither national nor county governments offer many supportive structures for companies proactively seeking to ensure accountability. No public reporting platform exists that companies could use to share their results and create transparency. Thus far, companies aiming to be publicly accountable use either the Access Observatory or their own websites for that purpose. However, most of the Kenyan stakeholders interviewed reported that they rarely used these channels to inform themselves about companies’ activities. Accountability could also be supported through regular progress review meetings with local stakeholders. However, these opportunities remain very limited. Some county governments do organize regular stakeholder meetings on health or even specifically on NCDs, during which implementing partners report on their activities and results. However, the frequency and quality of these forums varies widely from county to county.

“In some counties, like in Kericho, the county calls meetings. Probably because of this one guy at a hospital who was really enthusiastic about the program. He made sure we had a quarterly meeting for a World Diabetes Foundation program. Very rigid quarterly meetings. They are important. Some counties do it, others don’t.” (Interview #23, civil society representative)

These meetings are supposed to take place in each county on a regular basis as part of the general health governance system, but county governments generally depend on donor funding to support them. Moreover, the pharmaceutical companies are rarely actively involved, although they may be represented by their implementing partners. In some counties, interviewees were unaware of the corporate involvement in local NCD programs, as they only dealt with implementing partners that did not actively disclose their corporate funding.

“When we started the program, the company was not part of it. All I knew is that of course this NGO has some heavy funding and maybe they were looking for counties where they could work. They never told me where their funding was coming from.” (Interview #40, county government representative)

On the national level, NCD-specific learning and exchange forums involving corporations have taken place irregularly. In 2018 and 2019, national forums were hosted by the Ministry of Health in collaboration with the NCD Alliance Kenya, funded by Access Accelerated. Previous meetings also depended on donor funding preventing those meetings to function as an independent and regular accountability structure. With the outbreak of the COVID-19 pandemic, national NCD forums have been interrupted.

Discussion

Our study examined how Kenya is approaching the challenge of governing industry-led NCD initiatives. We seek to contribute to an understanding of how countries can assure that industry-led public health initiatives adhere to partnership principles and become an effective development tool. Kenya provided an apt study setting given the large number of industry-led initiatives being implemented there.

We identified several governance features in use to steer industry-led programs in Kenya: Informal norms exist to guide companies that intend to launch a NCD program. Structures, such as TWGs and stakeholder forums, are in place at the national level and in some counties—these can make it easier for companies to adhere to partnership principles while taking the onus off them to organize to convene stakeholders. This indicates that Kenya has already made important strides to address the challenges related to involving the industry in its NCD response. Once finalized, the Kenya Health Sector Partnership and Coordination Framework currently in development will provide additional tools to further strengthen the governing of industry-led initiatives [41]. Another promising governance initiative that interviewees reported is underway is the government’s effort to strengthen the NCD Interagency Coordinating Committee by tasking it with the implementation and governance of an upcoming National Strategy for Prevention and Control of NCDs 2021–2025 which is yet to be published. Other LMICs aiming to work more closely with the pharmaceutical industry in their NCD response may find Kenya’s existing governance approaches informative.

However, many gaps still exist in Kenya’s approach to governance of industry-led health programming. At a minimum, these gaps could undermine the effectiveness of industry-led programs in fully contributing to the country’s NCD response. More problematically, they could have negative effects on the health system if poorly designed programs use up limited resources. The first gap is the lack of formal regulation or other official benchmarks to guide program strategies and governance. In the absence of formal guidance, companies can interpret partnership principles on a case-by-case basis and to their own advantage. Although the government has clear, if informal, expectations regarding alignment, harmonization, and ownership, no informal norms exist for accountability and results management. One possible explanation for this gap is a fear of government and civil society partners that regulation would deter companies from further investments in the NCD programs that are filling a need in Kenya. However, stakeholders may be underestimating the importance that the companies place on such programs, which form a key part of corporate non-market strategies by building up networks, improving corporate reputations, and creating an enabling environment for future commercial gains [49]. As a future growth market for the pharmaceutical industry [50], Kenya is highly relevant to many companies. Thus, we anticipate that companies would be likely to follow any regulations imposed—indeed, they might welcome more guidance on the government’s expectations. Interviewees pointed to positive experiences in some other countries, notably Rwanda, where the government has been more proactive in steering and setting conditions for industry involvement.

Second, while the public sector is trying to expand enabling governance practices, many are not yet functioning well. The existing ad-hoc support for program design varies widely. Currently, the government, both nationally and in many counties, has not allocated resources to uphold and sufficiently finance permanent and robust structures that companies and other partners could utilize for better adherence to partnership principles. For example, stakeholder forums are supposed to be held regularly on the county level according to health governance regulations, but rarely take place. Instead, most enabling governance structures are currently provided by non-governmental actors, such as the accountability function of the Access Observatory [46]. Still, privately supported governance function could also only partially steer industry-led NCD initiatives. While important implementing partners such as AMPATH that work with multiple companies have leverage and expertise to shape strategy and implementation of corporate programs, these are only present in some counties or disease areas. National-level structures such as Access Accelerated and the Development Partners in Health roundtable are missing opportunities to promote harmonization. It is notable that while the traditional donors for health are not significantly supporting NCD interventions, they are also not coordinating or harmonizing with the industry players that are filling that gap.

Third, we want to specifically highlight the limited availability of epidemiological and health service data as a cross-cutting factor undermining coordination among stakeholders—this is a challenge that extends beyond just governing industry-led programs. Building up data repositories has been a factor for success in other areas of global health. For example, national governments have closely coordinated with external agencies to expand data collection and use in, for example, both HIV [51] and malnutrition [52]. Expanding collection of and access to data will also be a key element for better governance of the NCD sphere.

Many interviewees recognized the existing gaps in regulating and enabling governance and expressed support for closing them. Kenya has a window of opportunity to use this current stakeholder support to develop and implement stronger governance of industry-led public health programs. Traditional development donors could play a more active role by supporting Kenya and other countries on this path, for instance by contributing to ongoing efforts around the UN Sustainable Development Goals (SDG) Partnership Platform [53]. For such efforts to succeed, companies must be willing to cooperate and stop circumventing established processes, for example by using ties to high-level political leaders who make exceptions for them [54].

In addition to making recommendations specific to the Kenyan NCD context, this paper presents a tool for assessing national governance of other industry-led public health programs. While many scholars have argued for better governance of private sector involvement in public health, these calls lack specificity about what they imply for countries [22, 55]. Similarly, previous work analyzing country-level implementation of the Paris Declaration has ignored the roles of corporations as development partners [56], while focusing on specific aspects such as donor coordination [57]. While we developed the assessment tool for the case of pharmaceutical industry-led NCD programs, it could easily be adapted for use either in other sectors in public health or with other industries.

Limitations

Our assessment tool sought to integrate principles of aid effectiveness with perspectives on governance of corporate initiatives in a new way. Therefore, we could not adopt an existing validated framework. We do not claim that the proposed framework and tool are complete. Instead, we propose this tool as a starting point for further use, discussion, and development. For example, we focused only on how industry-led programs can be governed for effectiveness. Governance processes might also address other concerns, such as how to decide the degree to which a national health system is willing to work with industry-led programs in the first place.

The application of our assessment tool to the Kenyan NCD context was limited by the available data. As the local governance system is dynamic, official documents were often outdated or incomplete. Thus, we had to draw on interview accounts to expand the picture. While we tried to triangulate insights across interviews and by feeding preliminary results back to experts, we might have missed some relevant information.

Conclusion

This paper presented an assessment tool to study how a country governs pharmaceutical industry-led public health programs, which are growing in number—especially in LMICs. By using the tool to examine the case of the Kenyan NCD response, we generated insight into how normative calls for stronger country-level governance are being implemented. Other countries with growing pharmaceutical companies’ involvement in their NCD response may learn from Kenya about formulating clear rules of engagement and creating a supportive environment. For Kenya, these findings could contribute to the forthcoming health partnership framework and implementation of the new strategy for prevention and control of NCDs2021–2025.

The study highlights that LMIC governments face multiple challenges in developing and implementing comprehensive and functioning governance systems that can regulate and steer industry-led programs in public health. If traditional donors continue to provide only limited support to address NCDs, and as corporations become more active in working towards the SDGs, countries require support to strengthen the regulatory and enabling structures that can assure that industry-led programs become an effective development tool.

Availability of data and materials

The datasets generated and/or analyzed during the current study are not publicly available to ensure privacy of interviewees. Access to anonymized interview transcripts and archival data is available from the corresponding author on reasonable request.

References

  1. 1.

    Blowfield M, Dolan CS. Business as a development agent: evidence of possibility and improbability. Third World Q. 2014;35(1):22–42. https://doi.org/10.1080/01436597.2013.868982.

    Article  Google Scholar 

  2. 2.

    Kolk A, van Tulder R. International business, corporate social responsibility and sustainable development. Int Bus Rev. 2010;19(2):119–25. https://doi.org/10.1016/j.ibusrev.2009.12.003.

    Article  Google Scholar 

  3. 3.

    Crane A, Seitanidi MM. Social partnerships and responsible business: what, why and how? Soc. partnerships responsible bus. A res. Handb. London: Routledge; 2014.

    Google Scholar 

  4. 4.

    United Nations. Transforming our world: the 2030 Agenda for Sustainable Development [Internet] 2015. Available from: https://sustainabledevelopment.un.org/post2015/transformingourworld

  5. 5.

    Kolk A, Kourula A, Pisani N. Multinational enterprises and the sustainable development goals: what do we know and how to proceed? Transnatl Corp. 2017;24:9–32.

    Google Scholar 

  6. 6.

    Scheyvens R, Banks G, Hughes E. The Private Sector and the SDGs: The Need to Move Beyond ‘Business as Usual’. Sustain Dev. 2016;24(6):371–82. https://doi.org/10.1002/sd.1623.

    Article  Google Scholar 

  7. 7.

    Selsky JW, Parker B. Cross-sector partnerships to address social issues: challenges to theory and practice. J Manage. 2005;31:849–73.

    Google Scholar 

  8. 8.

    United Nations Global Compact. Transforming partnerships for the SDGs. 2018; Available from: https://www.unglobalcompact.org/docs/publications/Transforming_Partnerships_for_the_SDGs.pdf

    Google Scholar 

  9. 9.

    Rockers PC, Wirtz VJ, Umeh CA, Swamy PM, Laing RO. Industry-led access-to-medicines initiatives in low- and middle-income countries: strategies and evidence. Health Aff. 2017;36(4):706–13. https://doi.org/10.1377/hlthaff.2016.1213.

    Article  Google Scholar 

  10. 10.

    Allen LN. Financing national non-communicable disease responses. Glob Health Action. 2017;10(1):1–6. https://doi.org/10.1080/16549716.2017.1326687.

    Article  Google Scholar 

  11. 11.

    Access to Medicine Foundation. Access to Medicine Index 2018 [Internet]. Amsterdam; 2018. Available from: http://www.accesstomedicineindex.org/

  12. 12.

    Nugent R. A chronology of global assistance funding for NCD. Glob Heart. 2016;11(4):371–4. https://doi.org/10.1016/j.gheart.2016.10.027.

    Article  PubMed  Google Scholar 

  13. 13.

    Blowfield ME, Dolan C. Fairtrade facts and fancies: what Kenyan Fairtrade tea tells us about business’ role as development agent. J Bus Ethics. 2010;93(S2):143–62. https://doi.org/10.1007/s10551-010-0558-2.

    Article  Google Scholar 

  14. 14.

    Frynas JG. The false developmental promise of corporate social responsibility: evidence from multinational oil companies. Int Aff. 2005;81(3):17–9. https://doi.org/10.1111/j.1468-2346.2005.00470.x.

    Article  Google Scholar 

  15. 15.

    Vestergaard A, Murphy L, Morsing M, Langevang T. Cross-sector partnerships as Capitalism’s new development agents: reconceiving impact as empowerment. Bus Soc [internet]. 2019, 2020:1–38. Available from: https://doi.org/10.1177/0007650319845327.

  16. 16.

    Kolk A, Rivera-Santos M, Rufín C. Reviewing a decade of research on the “base/bottom of the pyramid” (BOP) concept. Bus Soc. 2014;53(3):338–77. https://doi.org/10.1177/0007650312474928.

    Article  Google Scholar 

  17. 17.

    Collins T, Mikkelsen B, Axelrod S. Interact, engage or partner? Working with the private sector for the prevention and control of noncommunicable diseases. Cardiovasc Diagn Ther [Internet]. 2018;9 Available from: http://cdt.amegroups.com/article/view/20806/23570.

  18. 18.

    Nishtar S. Public-private “partnerships” in health - a global call to action. Heal Res Policy Syst. 2004;2(1):1–7. https://doi.org/10.1186/1478-4505-2-5.

    Article  Google Scholar 

  19. 19.

    Richter J. Public-private partnerships for health: a trend with no alternatives? Development. 2004;47(2):43–8. https://doi.org/10.1057/palgrave.development.1100043.

    Article  Google Scholar 

  20. 20.

    Ruckert A, Labonté R. Public-private partnerships (ppps) in global health: the good, the bad and the ugly. Third World Q. 2014;35(9):1598–614. https://doi.org/10.1080/01436597.2014.970870.

    Article  Google Scholar 

  21. 21.

    WHO. Responding To Industry Initiatives To Increase Access To Medicines And Other Health Technologies In Countries [Internet]. 2017. Available from: https://apps.who.int/medicinedocs/en/m/abstract/Js23358en/

  22. 22.

    Clarke D, Doerr S, Hunter M, Schmets G, Paviza A. The private sector and universal health coverage. Bull World Health Organ. 2019;97(6):434–5. https://doi.org/10.2471/BLT.18.225540.

    Article  PubMed  PubMed Central  Google Scholar 

  23. 23.

    OECD. The Paris Declaration on Aid Effectiveness and the Accra Agenda for Action [Internet]. 2008. Available from: https://www.oecd.org/dac/effectiveness/parisdeclarationandaccraagendaforaction.htm

  24. 24.

    Glösenberg A, Foster L, Carr S. Good intentions are not enough: applying best practices from humanitarian aid to evaluate corporate social responsibility. In: McWilliams A, Rupp DE, Siegel DS, Stahl GK, Waldman DA, editors. Oxford Handb Corp Soc Responsib. Oxford: Oxford University Press; 2019.

    Google Scholar 

  25. 25.

    Holzscheiter A. International health partnership and IHP+. In: Hale T, Held D, editors. Handb Transnatl governance institutions Innov. Malden: Polity Press; 2011. p. 189–95.

    Google Scholar 

  26. 26.

    UHC. Global compact for progress towards universal health coverage [Internet]. 2030:2018 Available from: https://www.uhc2030.org/what-we-do/working-better-together/global-compact/.

  27. 27.

    Buse K, Harmer AM. Seven habits of highly effective global public-private health partnerships: practice and potential. Soc Sci Med. 2007;64(2):259–71. https://doi.org/10.1016/j.socscimed.2006.09.001.

    Article  PubMed  Google Scholar 

  28. 28.

    Rockers PC, Reich MR, Kettler H, Wirtz VJ. Commitment to impact: strengthening measurement of industry-led access-to-medicines programs. Heal Syst Reform. 2018;4(3):188–93. https://doi.org/10.1080/23288604.2018.1483710.

    Article  Google Scholar 

  29. 29.

    Umeh CA, Rockers PC, Laing RO, Wagh O, Wirtz VJ. Pharmaceutical industry-led partnerships focused on addressing the global burden of non-communicable diseases: a review of access Accelerated. Public Health. 2020;181:73–9. https://doi.org/10.1016/j.puhe.2019.12.008.

    CAS  Article  PubMed  Google Scholar 

  30. 30.

    Access Accelerated. Access Accelerated in action: key learnings in program design and implementation [internet]. 2019. Available from: https://accessaccelerated.org/news-and-events/key-learnings-in-program-design-implementation/

    Google Scholar 

  31. 31.

    Buse K, Walt G. Global public – private partnerships: part I – a new development in health? Bull World Health Organ. 2000;78(4):549–61.

    CAS  PubMed  PubMed Central  Google Scholar 

  32. 32.

    Laing RO, Rockers PC, Umeh CA, Wirtz VJ. Access Observatory 2019 Report [Internet] 2019. Available from: https://www.accessobservatory.org/annual-reports

  33. 33.

    Shiroya V, Neuhann F, Müller O, Deckert A. Challenges in policy reforms for non-communicable diseases: the case of diabetes in Kenya. Glob health action [internet]. 2019;12. Available from: https://doi.org/10.1080/16549716.2019.1611243, 2019.

  34. 34.

    Morgan C, Cira M, Karagu A, Asirwa FC, Brand NR, Buchanan Lunsford N, et al. The Kenya cancer research and control stakeholder program: evaluating a bilateral partnership to strengthen national cancer efforts. J Cancer Policy. 2018;17:38–44. https://doi.org/10.1016/j.jcpo.2017.03.012.

    Article  Google Scholar 

  35. 35.

    Kenya Ministry of Health. Kenya National Strategy for the Prevention and Control of Noncommunicable Disease 2015–2020 [Internet]. 2015. Available from: https://www.who.int/nmh/ncd-task-force/kenya-strategy-ncds-2015-2020.pdf?ua=1

  36. 36.

    Kenya Ministry of Health. Kenya Cancer Policy 2019–2030 [Internet]. 2019. Available from: https://www.iccp-portal.org/plans/kenya-cancer-policy-2019-2030

  37. 37.

    Kenya Ministry of Health. National Cancer Control Strategy 2017–2022 [Internet]. 2017. Available from: https://www.afro.who.int/news/kenya-launches-national-cancer-control-strategy-2017-2022

  38. 38.

    Kenya Ministry of Health. Kenya National Diabetes Strategy 2010–2015 [Internet]. 2010. Available from: https://www.worlddiabetesfoundation.org/files/kenya-ncds-national-diabetes-strategy-2015-2020

  39. 39.

    McCollum R, Limato R, Otiso L, Theobald S, Taegtmeyer M. Health system governance following devolution: comparing experiences of decentralisation in Kenya and Indonesia. BMJ Glob Heal. 2018;3(5):1–11. https://doi.org/10.1136/bmjgh-2018-000939.

    Article  Google Scholar 

  40. 40.

    Kenya Ministry of Health. Kenya Health Policy 2014–2030 [Internet]. 2014. Available from: http://publications.universalhealth2030.org/uploads/kenya_health_policy_2014_to_2030.pdf

  41. 41.

    Kenya Ministry of Health. Kenya Health Sector Partnership and Coordination Framework (Draft). 2019.

  42. 42.

    Umeh CA, Rockers PC, Laing R, Wagh O, Wirtz VJ. Public reporting on pharmaceutical industry-led access programs: Alignment with the WHO medicine programs evaluation checklist. J Pharm Policy Pract. Journal of Pharmaceutical Policy and Practice; 2020;13:1–9.

  43. 43.

    Beisheim M, Simon N. Meta-Governance of Partnerships for Sustainable Development: Actors’ Perspectives on How the UN Could Improve Partnerships’ Governance Services in Areas of Limited Statehood [Internet]. SFB-Governance Work. Pap. Ser. Berlin; 2015. Report No.: 68. Available from: http://ssrn.com/abstract=2680162

  44. 44.

    Beisheim M, Ellersiek A, Goltermann L, Kiamba P. Meta-governance of partnerships for sustainable development: actors’ perspectives in Kenya. Public Adm Dev. 2018;38(3):408–10. https://doi.org/10.1002/pad.1810.

    Article  Google Scholar 

  45. 45.

    Accelerated A. Access Accelerated flagship event @WHA71 [internet]. Youtube. 2018; Available from: https://www.youtube.com/watch?v=8QUFTj7-h74.

  46. 46.

    Kulkarni PJ, Laing RO, Rockers PC, Wirtz V. Access Observatory 2020 Report [internet]. Access Obs 2020. Available from: https://www.accessobservatory.org/annual-reports

  47. 47.

    Mercer T, Gardner A, Andama B, Chesoli C, Christoffersen-deb A, Dick J, et al. Leveraging the power of partnerships : spreading the vision for a population health care delivery model in western Kenya. Glob Health. 2018:1–11.

  48. 48.

    Johnson M, Wilkinson J, Gardner A, Kupfer LE, Kimaiyo S, Von Zinkernagel D. Global partnerships to support noncommunicable disease care in low and middle-income countries: lessons from HIV/AIDS. Aids. 2018;32(Supplement 1):S75–82. https://doi.org/10.1097/QAD.0000000000001880.

    Article  PubMed  Google Scholar 

  49. 49.

    Mellahi K, Frynas JG, Sun P, Siegel D. A review of the nonmarket strategy literature: toward a multi-theoretical integration. J Manage. 2016;42(1):143–73. https://doi.org/10.1177/0149206315617241.

    Article  Google Scholar 

  50. 50.

    Holt T, Lahrichi M, Mina J, Santos da Silva J. Insights into Pharmaceuticals and Medical Products; Africa: A continent of opportunity for pharma and patients [Internet]. McKinsey Co. 2015. Available from: https://www.mckinsey.com/industries/pharmaceuticals-and-medical-products/our-insights/africa-a-continent-of-opportunity-for-pharma-and-patients

  51. 51.

    UNAIDS. Data [Internet]. 2021. Available from: https://www.unaids.org/en/topic/data

  52. 52.

    WHO. Global Database on Child Growth and Malnutrition [Internet]. 2021. Available from: https://www.who.int/nutgrowthdb/database/en/

  53. 53.

    United Nations. SDG partnership platform Kenya [internet]. 2018. Available from: https://kenya.un.org/en/15284-sdg-partnership-platform

    Google Scholar 

  54. 54.

    Yu J, Lee SH. Bending the Rules or Changing Them? MNE Responses to Institutional Challenges in Transition Economies. Bus Soc [Internet]. 2019; Available from: https://doi.org/10.1177/0007650319843805.

  55. 55.

    Galea G, Mckee M. Public – private partnerships with large corporations: setting the ground rules for better health. Health Policy (New York). 2014;115(2-3):138–40. https://doi.org/10.1016/j.healthpol.2014.02.003.

    Article  Google Scholar 

  56. 56.

    OECD. The Evaluation of the Paris Declaration. Project Completion Report [Internet]. 2012. Available from: https://www.oecd.org/dac/evaluation/evaluationoftheimplementationoftheparisdeclaration.htm

  57. 57.

    Sundewall J, Forsberg BC, Jönsson K, Chansa C, Tomson G. The Paris declaration in practice: challenges of health sector aid coordination at the district level in Zambia. Heal Res Policy Syst. 2009;7(1):1–10. https://doi.org/10.1186/1478-4505-7-14.

    Article  Google Scholar 

Download references

Acknowledgements

The authors would like to thank all interviewees for taking the time to provide us with such useful contributions and insights. Particular thanks for their comments and edits on the manuscript go to Elizabeth Wala, David Makumi, and Jordan Javis. TB also thanks Professor Johanna Mair for feedback and guidance throughout this project.

Funding

TB is funded by a doctoral scholarship of the Heinrich Böll Foundation. Open Access funding enabled and organized by Projekt DEAL.

Author information

Affiliations

Authors

Contributions

TB conceived the study, collected, and analyzed data, and developed the manuscript. VW advised on the study design and methods, provided contacts for some of the interviewees, contributed to developing the analytical framework, and provided significant guidance and editing. CK provided expert background knowledge on NCD governance in Kenya, supported the analysis, and edited. All authors read and approved the final manuscript.

Authors’ information

TB has a Master’s in Public Policy from the Hertie School in Berlin, Germany. He is a doctoral candidate in governance at the school, studying the evolving role of the pharmaceutical industry in global health. TB previously worked in development cooperation on access to medicines with a focus on East Africa.

CK is a pharmacist by profession with a PhD in Medicinal Chemistry. She is Technical Advisor at NCDAK and a founder and current Medical Director of the Kenya Diabetes Management & Information Centre. CK also serves as a Member of the Kenyan NCD Child Task Force on Essential Medicines and contributes to NCD prevention, access to treatment and care, health system strengthening, research, advocacy, and policy development in the region. CK has previous experience in academia and research at Rhodes University (South Africa), University of Nairobi, United States International University-Africa and Kenya Medical Research Institute. She has also worked on drug regulation with the Pharmacy and Poisons Board, Ministry of Health, Kenya.

VJW is Professor of Global Health at the Boston University School of Public Health, where she is also Director of the World Health Organization Collaborating Center in Pharmaceutical Policy. Her research focuses on health system strengthening and program evaluations of medicines access and utilization. Her areas of interest and expertise include the role of the private sector in promoting equitable access and efficient use of medicines in low- and middle-income countries, medicines price analysis, generic medicines policies and access to medicines for non-communicable diseases. Between 2014 and 2016 she was the Co-Chair of The Lancet Commission on Essential Medicine Policies, which published its report Essential Medicines for Universal Health Coverage in Fall 2016.

Corresponding author

Correspondence to Tobias Bünder.

Ethics declarations

Ethics approval and consent to participate

We obtained the interviewees’ consent to interviews and recordings following the directions given by the ethics review of Strathmore University’s Institutional Review Board (SU-IERC0574/19). We have assured that all quotes of interviewees remain anonymous.

Consent for publication

n/a

Competing interests

Tobias Bünder [TB] does not declare any competing interests.

Catherine Karekezi [CK] does not declare any competing interests.

Veronika J. Wirtz [VJW] reports grants from Access Accelerated, Gilead Sciences, F. Hoffmann-La Roche, Sandoz International and Amgen outside the submitted work.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Bünder, T., Karekezi, C. & Wirtz, V. Governing industry involvement in the non-communicable disease response in Kenya. Global Health 17, 123 (2021). https://doi.org/10.1186/s12992-021-00776-3

Download citation

Keywords

  • Governance
  • Kenya
  • Pharmaceutical industry
  • Non-communicable diseases
  • Public-private partnerships
  • CSR